Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases
Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropria...
Gespeichert in:
| Veröffentlicht in: | Comparative clinical pathology 2018-09, Vol.27 (5), p.1133-1140 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1140 |
|---|---|
| container_issue | 5 |
| container_start_page | 1133 |
| container_title | Comparative clinical pathology |
| container_volume | 27 |
| creator | Rahamtalla, Fayza A. Abdalla, Mohammed S. M. Mudawi, Salma B. M. Kheir Elsid, Mohammed A. H. Shammat, Iman M. |
| description | Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (
n
= 33), cirrhosis (
n
= 33), and chronic hepatitis (
n
= 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively;
P
|
| doi_str_mv | 10.1007/s00580-018-2709-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2022455424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2022455424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1832-a42ab8e9911575a4091082f12ea0766488f6780bf6b1b648374c8ce097d7c653</originalsourceid><addsrcrecordid>eNp1kE9LAzEUxIMoWKsfwFvAa1dfspvd7LGU-gcKCvbgLWTTt3bLNqnJbsWLn93UFT15ejMwMw9-hFwyuGYAxU0AEBISYDLhBZQJPyIjlkcncvFy_KszdkrOQtgAMCHTdEQ-56FrtrprnKWuph22boteB5zQ6e3ThGq7OohkkdIW99gG2lj63K-0xYB0F4tou0Dfm25N1xi9M9i2fas9Ndqbxrqt_h4xa-9sY2jb7NHTVRMwPgnn5KTWbcCLnzsmy9v5cnafLB7vHmbTRWKYTHmiM64riWXJmCiEzqBkIHnNOGoo8jyTss4LCVWdV6yKNi0yIw1CWawKk4t0TK6G2Z13bz2GTm1c7238qDhwngmR8Sym2JAy3oXgsVY7H9n4D8VAHSirgbKKlNWBsuKxw4dOiFn7iv5v-f_SF85Efu8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2022455424</pqid></control><display><type>article</type><title>Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases</title><source>SpringerLink Journals</source><creator>Rahamtalla, Fayza A. ; Abdalla, Mohammed S. M. ; Mudawi, Salma B. M. ; Kheir Elsid, Mohammed A. H. ; Shammat, Iman M.</creator><creatorcontrib>Rahamtalla, Fayza A. ; Abdalla, Mohammed S. M. ; Mudawi, Salma B. M. ; Kheir Elsid, Mohammed A. H. ; Shammat, Iman M.</creatorcontrib><description>Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (
n
= 33), cirrhosis (
n
= 33), and chronic hepatitis (
n
= 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively;
P
< 0.01). Serum alpha-fetoprotein (AFP) and
Lens culinaris
agglutinin-reactive (AFP-L3) levels were also significantly elevated in HCC patients compared to healthy controls (130.76 versus 5.59 ng/ml;
P
< 0.01) and (59.76 versus 0.49 ng/ml;
P
< 0.01), respectively. The combination between telomerase and AFP or AFPL-3 lead to increased telomerase sensitivity (85 and 79%, respectively).Telomerase was found to be further sensitive in patients with a tumor size of less than 5 cm as well as to tumors of more than 5 cm. Two healthy control samples showed an increase in telomerase level. The combined use of telomerase, AFP, and AFP-L3 levels might be useful for achieving better sensitivity for HCC patients.</description><identifier>ISSN: 1618-5641</identifier><identifier>EISSN: 1618-565X</identifier><identifier>DOI: 10.1007/s00580-018-2709-2</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Biomarkers ; Cirrhosis ; Enzyme-linked immunosorbent assay ; Enzymes ; Hematology ; Hepatitis ; Hepatocellular carcinoma ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Pathology ; Telomerase ; Tumors ; α-Fetoprotein</subject><ispartof>Comparative clinical pathology, 2018-09, Vol.27 (5), p.1133-1140</ispartof><rights>Springer-Verlag London Ltd., part of Springer Nature 2018</rights><rights>Comparative Clinical Pathology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1832-a42ab8e9911575a4091082f12ea0766488f6780bf6b1b648374c8ce097d7c653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00580-018-2709-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00580-018-2709-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Rahamtalla, Fayza A.</creatorcontrib><creatorcontrib>Abdalla, Mohammed S. M.</creatorcontrib><creatorcontrib>Mudawi, Salma B. M.</creatorcontrib><creatorcontrib>Kheir Elsid, Mohammed A. H.</creatorcontrib><creatorcontrib>Shammat, Iman M.</creatorcontrib><title>Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases</title><title>Comparative clinical pathology</title><addtitle>Comp Clin Pathol</addtitle><description>Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (
n
= 33), cirrhosis (
n
= 33), and chronic hepatitis (
n
= 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively;
P
< 0.01). Serum alpha-fetoprotein (AFP) and
Lens culinaris
agglutinin-reactive (AFP-L3) levels were also significantly elevated in HCC patients compared to healthy controls (130.76 versus 5.59 ng/ml;
P
< 0.01) and (59.76 versus 0.49 ng/ml;
P
< 0.01), respectively. The combination between telomerase and AFP or AFPL-3 lead to increased telomerase sensitivity (85 and 79%, respectively).Telomerase was found to be further sensitive in patients with a tumor size of less than 5 cm as well as to tumors of more than 5 cm. Two healthy control samples showed an increase in telomerase level. The combined use of telomerase, AFP, and AFP-L3 levels might be useful for achieving better sensitivity for HCC patients.</description><subject>Biomarkers</subject><subject>Cirrhosis</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Hematology</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pathology</subject><subject>Telomerase</subject><subject>Tumors</subject><subject>α-Fetoprotein</subject><issn>1618-5641</issn><issn>1618-565X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kE9LAzEUxIMoWKsfwFvAa1dfspvd7LGU-gcKCvbgLWTTt3bLNqnJbsWLn93UFT15ejMwMw9-hFwyuGYAxU0AEBISYDLhBZQJPyIjlkcncvFy_KszdkrOQtgAMCHTdEQ-56FrtrprnKWuph22boteB5zQ6e3ThGq7OohkkdIW99gG2lj63K-0xYB0F4tou0Dfm25N1xi9M9i2fas9Ndqbxrqt_h4xa-9sY2jb7NHTVRMwPgnn5KTWbcCLnzsmy9v5cnafLB7vHmbTRWKYTHmiM64riWXJmCiEzqBkIHnNOGoo8jyTss4LCVWdV6yKNi0yIw1CWawKk4t0TK6G2Z13bz2GTm1c7238qDhwngmR8Sym2JAy3oXgsVY7H9n4D8VAHSirgbKKlNWBsuKxw4dOiFn7iv5v-f_SF85Efu8</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Rahamtalla, Fayza A.</creator><creator>Abdalla, Mohammed S. M.</creator><creator>Mudawi, Salma B. M.</creator><creator>Kheir Elsid, Mohammed A. H.</creator><creator>Shammat, Iman M.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20180901</creationdate><title>Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases</title><author>Rahamtalla, Fayza A. ; Abdalla, Mohammed S. M. ; Mudawi, Salma B. M. ; Kheir Elsid, Mohammed A. H. ; Shammat, Iman M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1832-a42ab8e9911575a4091082f12ea0766488f6780bf6b1b648374c8ce097d7c653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomarkers</topic><topic>Cirrhosis</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Hematology</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pathology</topic><topic>Telomerase</topic><topic>Tumors</topic><topic>α-Fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rahamtalla, Fayza A.</creatorcontrib><creatorcontrib>Abdalla, Mohammed S. M.</creatorcontrib><creatorcontrib>Mudawi, Salma B. M.</creatorcontrib><creatorcontrib>Kheir Elsid, Mohammed A. H.</creatorcontrib><creatorcontrib>Shammat, Iman M.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Comparative clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahamtalla, Fayza A.</au><au>Abdalla, Mohammed S. M.</au><au>Mudawi, Salma B. M.</au><au>Kheir Elsid, Mohammed A. H.</au><au>Shammat, Iman M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases</atitle><jtitle>Comparative clinical pathology</jtitle><stitle>Comp Clin Pathol</stitle><date>2018-09-01</date><risdate>2018</risdate><volume>27</volume><issue>5</issue><spage>1133</spage><epage>1140</epage><pages>1133-1140</pages><issn>1618-5641</issn><eissn>1618-565X</eissn><abstract>Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (
n
= 33), cirrhosis (
n
= 33), and chronic hepatitis (
n
= 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively;
P
< 0.01). Serum alpha-fetoprotein (AFP) and
Lens culinaris
agglutinin-reactive (AFP-L3) levels were also significantly elevated in HCC patients compared to healthy controls (130.76 versus 5.59 ng/ml;
P
< 0.01) and (59.76 versus 0.49 ng/ml;
P
< 0.01), respectively. The combination between telomerase and AFP or AFPL-3 lead to increased telomerase sensitivity (85 and 79%, respectively).Telomerase was found to be further sensitive in patients with a tumor size of less than 5 cm as well as to tumors of more than 5 cm. Two healthy control samples showed an increase in telomerase level. The combined use of telomerase, AFP, and AFP-L3 levels might be useful for achieving better sensitivity for HCC patients.</abstract><cop>London</cop><pub>Springer London</pub><doi>10.1007/s00580-018-2709-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1618-5641 |
| ispartof | Comparative clinical pathology, 2018-09, Vol.27 (5), p.1133-1140 |
| issn | 1618-5641 1618-565X |
| language | eng |
| recordid | cdi_proquest_journals_2022455424 |
| source | SpringerLink Journals |
| subjects | Biomarkers Cirrhosis Enzyme-linked immunosorbent assay Enzymes Hematology Hepatitis Hepatocellular carcinoma Liver cancer Liver cirrhosis Liver diseases Medicine Medicine & Public Health Oncology Original Article Pathology Telomerase Tumors α-Fetoprotein |
| title | Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T10%3A15%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estimation%20of%20telomerase,%20AFP,%20and%20AFP-L3%20levels%20in%20Sudanese%20patients%20with%20hepatocellular%20carcinoma%20and%20chronic%20liver%20diseases&rft.jtitle=Comparative%20clinical%20pathology&rft.au=Rahamtalla,%20Fayza%20A.&rft.date=2018-09-01&rft.volume=27&rft.issue=5&rft.spage=1133&rft.epage=1140&rft.pages=1133-1140&rft.issn=1618-5641&rft.eissn=1618-565X&rft_id=info:doi/10.1007/s00580-018-2709-2&rft_dat=%3Cproquest_cross%3E2022455424%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2022455424&rft_id=info:pmid/&rfr_iscdi=true |